[Effect of infusion therapy on intrauterine fetal growth retardation (author's transl)].
It is requested for the control to the intrauterine fetal growth retardation (IUGR) to clarify the cause-and-effect relationship and to take the proper treatment under such a precondition. Following report covers the clinical report on the maternal infusion therapy mainly consisting of amino acids. 1) In the cases, to which the diagnosis of IUGR was given on basis of the development of symphisis-fundus length on the pregnogram and the fetal biparietal diameter (BPD), the occurrence of appropriate-for-gestational-age (AGA) is as extremely high as 44.5% when it is felt without treatment. In the abnormal patterns of symphisis-fundus length, consisting mainly of the threatened premature labor, the differential diagnosis is needed to the outward IUGR. 2) As the effect of the maternal infusion therapy mainly of amino acids on IUGR, given in addition to the oral nutrition, the increase of placental weight and fetal weight was observed at around NP-Cal/N of 99-116. No abnormality was observed in the maternal renal and liver function. 3) As the result of the maternal infusion therapy to 131 cases of IUGR, the occurrence ratio of the small-for-gestational-age (SGA) was 26.7%. No case of perinatal death or congenital malformation was observed.
D000328:Adult; D000596:Amino Acids / Q000008:administration & dosage*; D001724:Birth Weight; D003937:Diagnosis, Differential; D005260:Female; D005317:Fetal Growth Retardation / Q000175:diagnosis / Q000628:therapy*; D005323:Fetal Monitoring; D006801:Humans; D007231:Infant, Newborn; D007263:Infusions, Parenteral; D008320:Maltose / Q000008:administration & dosage; D011247:Pregnancy
D000596:Amino Acids; D008320:Maltose